Serpil OĞUZTÜZÜN, Murat KILIÇ, Nisa TANDOĞAN, Latif ÖZTÜRK

Usefulness of CA 15-3 for breast or ovarian primary sites in metastatic adenocarcinoma of pleural fluid

This study was conducted to evaluate the diagnostic value of CA 15-3, mammaglobin, c-erbB-2, estrogen receptor (ER), progesterone receptor (PR), CK 20, and CA 125 for detecting metastatic breast and ovarian carcinoma in pleural fluids. The material under study consisted of 26 pleural effusions from invasive breast and ovarian cancer patients from the Hannover Cytopathology Institute. Expressions of these markers were studied using immunocytochemistry. All of the breast cancer cases studied showed a positive reaction with CA 15-3, while only 36% with mammaglobin, 21% with c-erbB-2, 36% with ER, and 7% with PR were positive. The sensitivities of CK 20, CA 15-3, and CA 125 as markers for metastatic ovarian carcinoma were 43%, 88%, and 55%, respectively. Our results indicate that CA 15-3 has a higher sensitivity than other tumor markers for diagnosing metastatic breast and ovarian carcinoma in pleural fluids.

Anahtar Kelimeler:

Key words: Pleura, metastasis, breast cancer, ovarian cancer, CA 15-3, cytology

Usefulness of CA 15-3 for breast or ovarian primary sites in metastatic adenocarcinoma of pleural fluid

Keywords:

Key words: Pleura, metastasis, breast cancer, ovarian cancer, CA 15-3, cytology,

PDF

___

Lee BH, Hecht JL, Pinkus JL et al. WT1, estrogen receptor, and progesterone receptor as markers for breast or ovarian primary sites in metastatic adenocarcinoma to body fl uids. Am J Clin Pathol 117: 745-750, 2002. 2. Shitrit D, Zingerman B, Shitrit ABG et al. Diagnostic value of CYFRA21-1, CEA, CA 19-9, CA 15-3, and CA 125 assays in pleural eff usions: analysis of 116 cases and review of the literature. Oncologist 10: 501-507, 2005.
Byrne J, Horgas PG, England S et al. A preliminary report on the usefulness of monoclonal antibodies to CA15-3 and MCA in the detection of micrometastases in axillary lymph nodes draining primary breast carcinoma. Eur J Cancer 28: 658-60, 1992.
Oğuztüzün S, Atay M, Özhavzalı M et al. Comparison and evaluation of CA 15-3, c-erbB-2, ER, and PR tumor markers in pleural fl uid cytology from metastatic breast cancer as a diagnostic tool. Turk J Cancer 39: 45-50, 2009.
Szpak CA, Johnston VW, Lottich SC et al. Patterns of reactivity of four novel monoclonal antibodies (B72.3, DF3, B1.1, B6.2) with cells in malignant and benign eff usions. Acta Cytol 28: 356-367, 1984.
Huang Y, Zimmerman RL, Bibbo M. Diagnostic value of CA15-3 antibody in detecting metastatic adenocarcinoma. Anal Quant Cytol Histol 26: 259-262, 2004.
Geraghty JG, Coveney EC, Sherry F et al. CA15-3 in patients with locoregional and metastatic breast carcinoma. Cancer 70: 2831-2834, 1992.
Fehm T, Jager W, Kramer S et al. Prognostic signifi cance of serum Her2 and CA15-3 at the time of diagnosis of metastatic breast cancer. Anticancer Res 24: 1987-1992, 2004.
Scambia G, Benedetti Panici P, Baiocchi G et al. CA15-3 as a tumor marker in gynecological malignancies. Gynecol Oncol 30: 265-273, 1988.
Tuxen MK, Soletormos G, Dombernowsky P. Tumor markers in the management of patients with ovarian cancer. Cancer Treat Rev 21: 215-245, 1995.
Dupont J, Tanwar MK, Th aler HT et al. Early detection and prognosis of ovarian cancer using serum YKL-40. J Clin Oncol 22: 3330-3339, 2004.